Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001641172-25-001182
Filing Date
2025-03-28
Accepted
2025-03-28 16:05:19
Documents
18
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-ka.htm   iXBRL 10-K/A 405790
2 ex23-1.htm EX-23.1 2675
3 ex31-1.htm EX-31.1 11431
4 ex31-2.htm EX-31.2 11326
5 ex32-1.htm EX-32.1 11676
  Complete submission text file 0001641172-25-001182.txt   1052483

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE evfm-20241231.xsd EX-101.SCH 44679
7 XBRL DEFINITION FILE evfm-20241231_def.xml EX-101.DEF 6236
8 XBRL LABEL FILE evfm-20241231_lab.xml EX-101.LAB 213724
9 XBRL PRESENTATION FILE evfm-20241231_pre.xml EX-101.PRE 72339
20 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 7482
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36754 | Film No.: 25785908
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)